Loading
Life sciences · Journal article
Virology Journal · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Although numerous risk factors influencing cancer progression have been identified, many aspects of the relationship between oncoviruses and tumor development remain poorly understood. One signalling pathway that has attracted considerable attention is the Notch signalling pathway, whose dysregulation by oncoviruses disrupts core cellular processes including cell proliferation, apoptosis resistance, stem cell maintenance, epithelial‑mesenchymal transition, and immune evasion—events that collectively drive malignant transformation and carcinogenesis. In this review, we summarize and critically discuss the key molecular mechanisms underlying the interaction between Notch signalling and major human oncoviruses, including human papillomavirus (HPV), human T‑lymphotropic virus type 1 (HTLV‑1), Epstein–Barr virus (EBV), Kaposi’s sarcoma‑associated herpesvirus (KSHV), hepatitis B virus (HBV), and hepatitis C virus (HCV). We also highlight unresolved questions in the field and outline how deeper understanding of this virus–Notch crosstalk may inform future basic research, identify novel diagnostic biomarkers, and guide the development of targeted antiviral or anti‑cancer therapies.